- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners
The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is Alabama’s only cancer center designated by the National Cancer Institute and is a national leader in driving cancer research, advancing new cancer treatments, engaging communities in cancer prevention and early detection initiatives, and training the next generation of cancer physicians and scientists. Since it was established in 1971, the Cancer Center has been continuously funded for 48 years and has become a world-renowned institution for cancer research, cancer care and the delivery of that care to all people.
Connect with us:
Latest from O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Sleckman to lead O'Neal Comprehensive Cancer Center
October 23, 2019
Article
Barry Paul Sleckman, MD, PhD, has been named director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
Dr. Magi-Galluzzi on Preventing Overtreatment of Prostate Cancer
July 15, 2019
Video
Cristina Magi-Galluzzi, MD, PhD, discusses the importance of properly diagnosing patients with prostate cancer to avoid overtreatment.
New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer
July 04, 2019
Article
The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.
Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies
August 14, 2018
Video
Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.
Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer
June 13, 2018
Video
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Older CRC Patients at Increased Risk for New-Onset Cardiotoxicity
January 23, 2018
Article
Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.
Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML
August 25, 2017
Video
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.
Dr. Erba on Unique Characteristics of CPX-351 in AML
August 22, 2017
Video
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer
August 16, 2017
Video
Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.
Dr. Erba on the FDA Approval of CPX-351 in AML
August 11, 2017
Video
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
Dr. Arend Discusses MSI Testing in Gynecologic Malignancies
August 10, 2017
Video
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.
Dr. Arend Discusses Targets in Endometrial Cancer
August 02, 2017
Video
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.
Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer
July 07, 2017
Video
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
Dr. Spencer on Radiation Therapy for Patients With Head and Neck Cancer
April 14, 2016
Video
Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.